IDiyas

For the Inventor, By the Inventor

Woodcliff Lake, NJ, United States of America

William B Wright, Jr

USPTO Granted Patents = 33

Average Co-Inventor Count = 2.2

ph-index = 8

Forward Citations = 160(Granted Patents)


Location History:

  • Bergen, NJ (US) (1987 - 1988)
  • Woodcliff Lake, NJ (US) (1976 - 1990)

Company Filing History:

goldMedal33 out of 3,580 
 
American Cyanamid Company
 patents

Years Active: 1976-1990

Loading Chart...
33 patents (USPTO):Explore Patents
1. 4892885 - Esters of (triarylphosphoranylidene)carbamic acid for effecting diuresis (1990-01-09),
2. 4782064 - 2-heteroaryl-alkyl-1H-benz[de]-isoquinoline-1,3(2H)-diones (1988-11-01),
3. 4753944 - Pharmaceutical methods of using 3-heteroarylalkyl-4-quinazolinones (1988-06-28),
4. 4743610 - N-[.omega.(3-pyridinyl)alkyl]benzamides, useful as thromboxane (1988-05-10),
5. 4710502 - 3-heteroarylalkyl-4-quinazolinones (1987-12-01),
6. 4684654 - 3-heteroalkyl-2,4-quinzaolinediones (1987-08-04),
7. 4680293 - 3-imidazolylalkyl-, triazolylalkyl-, (1987-07-14),
8. 4619941 - N-[(1H-imidazol-1-yl)alkyl]-1H-indolecarboxamides useful as thromboxane (1986-10-28),
9. 4610981 - N-[(1H-imidazol-1-yl) and (1986-09-09),
10. 4576957 - N-(Substituted phenyl)-N'-[(1H-imidazol-1-yl) and (1986-03-18),
11. 4568687 - N-[2-4-(1H-Imidazol-1-yl)alkyl]-arylamides and pharmaceutical (1986-02-04),
12. 4568685 - N-[(1H-1,2,4-Triazol-1-yl)alkyl]-arylamides (1986-02-04),
13. 4555519 - Thromboxane synthetase enzyme inhibiting N-[(1H-imidazol-1-yl) and (1985-11-26),
14. 4542145 - Substituted N-[(1H-1,2,4-triazol-1-yl)-alkyl]heteroarylcarboxamides (1985-09-17),
15. 4489089 - Substituted N-[.omega.-(1H-imidazol-1-yl)alkyl]-amides (1984-12-18),

Title: **William B. Wright, Jr.: Innovator in Therapeutic Solutions**

Introduction

William B. Wright, Jr. is a notable inventor based in Woodcliff Lake, NJ, USA, with an impressive portfolio consisting of 33 patents. His innovative work primarily focuses on advancements in therapeutic agents, contributing significantly to the fields of diuretics and hypertension treatments.

Latest Patents

Among his recent contributions to the patent landscape are two significant inventions. The first is titled "Esters of (triarylphosphoranylidene)carbamic acid for effecting diuresis," which involves novel esters that serve as effective diuretic agents. This innovation highlights Wright's impact on developing medical compounds that can facilitate fluid regulation in patients. The second patent, "2-heteroaryl-alkyl-1H-benz[de]-isoquinoline-1,3(2H)-diones," encompasses new compounds that act as inhibitors of thromboxane synthetase. This invention has promising implications for treating hypertension and myocardial ischemia, showcasing his dedication to addressing critical health challenges.

Career Highlights

Wright is affiliated with the American Cyanamid Company, where he has been instrumental in advancing research and development. His extensive experience and innovative mindset have positioned him as a key contributor within the organization, allowing for the translation of scientific discoveries into practical applications.

Collaborations

Throughout his career, Wright has collaborated with talented colleagues, including Andrew S. Tomcufcik and Joseph W. Marsico, Jr. These partnerships underscore the importance of teamwork in research and innovation, as they collectively strive towards developing cutting-edge pharmaceutical solutions.

Conclusion

William B. Wright, Jr.'s contributions to the field of therapeutics through his patents reflect his commitment to improving healthcare outcomes. His work continues to influence medical research and demonstrates the significant role of innovation in addressing complex health issues.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…